Evidence map›Paper›PMID 25236395›Full record

ReviewCell death and differentiation2015

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

L Galluzzi, J M Bravo-San Pedro, I Vitale, S A Aaronson, J M Abrams, D Adam, E S Alnemri, L Altucci, D Andrews, M Annicchiarico-Petruzzelli and 98 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell death and differentiation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 507 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
507citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

507 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

447 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

108 authors.

L Galluzzi1] Gustave Roussy Cancer Center, Villejuif, France [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
J M Bravo-San Pedro1] Gustave Roussy Cancer Center, Villejuif, France [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [3] INSERM, U1138, Gustave Roussy, Paris, France.
I VitaleRegina Elena National Cancer Institute, Rome, Italy.
S A AaronsonDepartment of Oncological Sciences, The Tisch Cancer Institute, Ichan School of Medicine at Mount Sinai, New York, NY, USA.
J M AbramsDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, TX, USA.
D AdamInstitute of Immunology, Christian-Albrechts University, Kiel, Germany.
E S AlnemriDepartment of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, USA.
L AltucciDipartimento di Biochimica, Biofisica e Patologia Generale, Seconda Università degli Studi di Napoli, Napoli, Italy.
D AndrewsDepartment of Biochemistry and Medical Biophysics, University of Toronto, Toronto, ON, Canada.
M Annicchiarico-PetruzzelliBiochemistry Laboratory, Istituto Dermopatico dell'Immacolata - Istituto Ricovero Cura Carattere Scientifico (IDI-IRCCS), Rome, Italy.
E H BaehreckeDepartment of Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.
N G BazanNeuroscience Center of Excellence, School of Medicine, New Orleans, LA, USA.
M J Bertrand1] VIB Inflammation Research Center, Ghent, Belgium [2] Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
K Bianchi1] Barts Cancer Institute, Cancer Research UK Centre of Excellence, London, UK [2] Queen Mary University of London, John Vane Science Centre, London, UK.
M V BlagosklonnyDepartment of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA.
K BlomgrenKarolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
C BornerInstitute of Molecular Medicine and Spemann Graduate School of Biology and Medicine, Albert-Ludwigs University, Freiburg, Germany.
D E Bredesen1] Buck Institute for Research on Aging, Novato, CA, USA [2] Department of Neurology, University of California, San Francisco (UCSF), San Francisco, CA, USA.
C Brenner1] INSERM, UMRS769, Châtenay Malabry, France [2] LabEx LERMIT, Châtenay Malabry, France [3] Université Paris Sud/Paris XI, Orsay, France.
M CampanellaDepartment of Comparative Biomedical Sciences and Consortium for Mitochondrial Research, University College London (UCL), London, UK.
E CandiDepartment of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
F Cecconi1] Laboratory of Molecular Neuroembryology, IRCCS Fondazione Santa Lucia, Rome, Italy [2] Department of Biology, University of Rome Tor Vergata; Rome, Italy [3] Unit of Cell Stress and Survival, Danish Cancer Society Research Center, Copenhagen, Denmark.
F K ChanDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, USA.
N S ChandelDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
E H ChengHuman Oncology and Pathogenesis Program and Department of Pathology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
J E ChipukDepartment of Oncological Sciences, The Tisch Cancer Institute, Ichan School of Medicine at Mount Sinai, New York, NY, USA.
J A CidlowskiLaboratory of Signal Transduction, National Institute of Environmental Health Sciences (NIEHS), National Institute of Health (NIH), North Carolina, NC, USA.
A CiechanoverTumor and Vascular Biology Research Center, The Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel.
T M Dawson1] Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering (ICE), Departments of Neurology, Pharmacology and Molecular Sciences, Solomon H Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
V L Dawson1] Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering (ICE), Departments of Neurology, Pharmacology and Molecular Sciences, Solomon H Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA [2] Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
V De LaurenziDepartment of Experimental and Clinical Sciences, Gabriele d'Annunzio University, Chieti, Italy.
R De MariaRegina Elena National Cancer Institute, Rome, Italy.
K-M DebatinDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
N Di DanieleDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
V M DixitDepartment of Physiological Chemistry, Genentech, South San Francisco, CA, USA.
B D DynlachtDepartment of Pathology and Cancer Institute, Smilow Research Center, New York University School of Medicine, New York, NY, USA.
W S El-DeiryLaboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA.
G M Fimia1] Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Lecce, Italy [2] Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto Ricovero Cura Carattere Scientifico (IRCCS), Rome, Italy.
R A FlavellDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
S FuldaInstitute for Experimental Cancer Research in Pediatrics, Goethe University, Frankfurt, Germany.
C Garrido1] INSERM, U866, Dijon, France [2] Faculty of Medicine, University of Burgundy, Dijon, France.
M-L GougeonAntiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, Institut Pasteur, Paris, France.
D R GreenDepartment of Immunology, St Jude's Children's Research Hospital, Memphis, TN, USA.
H GronemeyerDepartment of Functional Genomics and Cancer, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France.
G HajnoczkyDepartment of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA.
J M HardwickW Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD, USA.
M O HengartnerInstitute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
H IchijoLaboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
B JosephDepartment of Oncology-Pathology, Cancer Centrum Karolinska (CCK), Karolinska Institute, Stockholm, Sweden.
P J JostMedical Department for Hematology, Technical University of Munich, Munich, Germany.
T KaufmannInstitute of Pharmacology, Medical Faculty, University of Bern, Bern, Switzerland.
O Kepp1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [2] INSERM, U1138, Gustave Roussy, Paris, France [3] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
D J KlionskyLife Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
R A Knight1] Medical Molecular Biology Unit, Institute of Child Health, University College London (UCL), London, UK [2] Medical Research Council Toxicology Unit, Leicester, UK.
S Kumar1] Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia [2] School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia.
J J LemastersDepartments of Drug Discovery and Biomedical Sciences and Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
B Levine1] Center for Autophagy Research, University of Texas, Southwestern Medical Center, Dallas, TX, USA [2] Howard Hughes Medical Institute (HHMI), Chevy Chase, MD, USA.
A LinkermannDivision of Nephrology and Hypertension, Christian-Albrechts University, Kiel, Germany.
S A Lipton1] The Scripps Research Institute, La Jolla, CA, USA [2] Sanford-Burnham Center for Neuroscience, Aging, and Stem Cell Research, La Jolla, CA, USA [3] Salk Institute for Biological Studies, La Jolla, CA, USA [4] University of California, San Diego (UCSD), San Diego, CA, USA.
R A LockshinDepartment of Biological Sciences, St. John's University, Queens, NY, USA.
C López-OtínDepartment of Biochemistry and Molecular Biology, Faculty of Medecine, Instituto Universitario de Oncología (IUOPA), University of Oviedo, Oviedo, Spain.
E LugliUnit of Clinical and Experimental Immunology, Humanitas Clinical and Research Center, Milan, Italy.
F MadeoInstitute of Molecular Biosciences, University of Graz, Graz, Austria.
W Malorni1] Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanita (ISS), Roma, Italy [2] San Raffaele Institute, Sulmona, Italy.
J-C Marine1] Laboratory for Molecular Cancer Biology, Center for the Biology of Disease, Leuven, Belgium [2] Laboratory for Molecular Cancer Biology, Center of Human Genetics, Leuven, Belgium.
S J MartinDepartment of Genetics, The Smurfit Institute, Trinity College, Dublin, Ireland.
J-C MartinouDepartment of Cell Biology, University of Geneva, Geneva, Switzerland.
J P MedemaLaboratory for Experiments Oncology and Radiobiology (LEXOR), Academic Medical Center (AMC), Amsterdam, The Netherlands.
P MeierInstitute of Cancer Research, The Breakthrough Toby Robins Breast Cancer Research Centre, London, UK.
S MelinoDepartment of Chemical Sciences and Technologies, University of Rome Tor Vergata, Rome, Italy.
N MizushimaGraduate School and Faculty of Medicine, University of Tokyo, Tokyo, Japan.
U MollDepartment of Pathology, Stony Brook University, Stony Brook, NY, USA.
C Muñoz-PinedoCell Death Regulation Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
G NuñezDepartment of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
A OberstDepartment of Immunology, University of Washington, Seattle, WA, USA.
T PanaretakisDepartment of Oncology-Pathology, Cancer Centrum Karolinska (CCK), Karolinska Institute, Stockholm, Sweden.
J M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.
M E PeterDepartment of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
M Piacentini1] Department of Biology, University of Rome Tor Vergata; Rome, Italy [2] Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto Ricovero Cura Carattere Scientifico (IRCCS), Rome, Italy.
P PintonDepartment of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology and LTTA Center, University of Ferrara, Ferrara, Italy.
J H PrehnDepartment of Physiology and Medical Physics, Royal College of Surgeons, Dublin, Ireland.
H PuthalakathDepartment of Biochemistry, La Trobe Institute of Molecular Science, La Trobe University, Melbourne, Australia.
G A RabinovichLaboratory of Immunopathology, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
K S RavichandranDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.
R RizzutoDepartment Biomedical Sciences, University of Padova, Padova, Italy.
C M RodriguesResearch Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
D C RubinszteinDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, Cambridge, UK.
T RudelDepartment of Microbiology, University of Würzburg; Würzburg, Germany.
Y ShiSoochow Institute for Translational Medicine, Soochow University, Suzhou, China.
H-U SimonInstitute of Pharmacology, University of Bern, Bern, Switzerland.
B R Stockwell1] Howard Hughes Medical Institute (HHMI), Chevy Chase, MD, USA [2] Departments of Biological Sciences and Chemistry, Columbia University, New York, NY, USA.
G Szabadkai1] Department Biomedical Sciences, University of Padova, Padova, Italy [2] Department of Cell and Developmental Biology and Consortium for Mitochondrial Research, University College London (UCL), London, UK.
S W Tait1] Cancer Research UK Beatson Institute, Glasgow, UK [2] Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
H L TangW Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, MD, USA.
N Tavernarakis1] Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Crete, Greece [2] Department of Basic Sciences, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
Y TsujimotoOsaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
T Vanden Berghe1] VIB Inflammation Research Center, Ghent, Belgium [2] Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
P Vandenabeele1] VIB Inflammation Research Center, Ghent, Belgium [2] Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium [3] Methusalem Program, Ghent University, Ghent, Belgium.
A VillungerDivision of Developmental Immunology, Biocenter, Medical University Innsbruck, Innsbruck, Austria.
E F WagnerCancer Cell Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
H WalczakCentre for Cell Death, Cancer and Inflammation (CCCI), UCL Cancer Institute, University College London (UCL), London, UK.
E WhiteRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
W G Wood1] Department of Pharmacology, University of Minnesota School of Medicine, Minneapolis, MN, USA [2] Geriatric Research, Education and Clinical Center, VA Medical Center, Minneapolis, MN, USA.
J YuanDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.
Z Zakeri1] Department of Biology, Queens College, Queens, NY, USA [2] Graduate Center, City University of New York (CUNY), Queens, NY, USA.
B Zhivotovsky1] Division of Toxicology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden [2] Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia.
G Melino1] Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy [2] Medical Research Council Toxicology Unit, Leicester, UK.
G Kroemer1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France [2] Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France [3] INSERM, U1138, Gustave Roussy, Paris, France [4] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

Funding

UNDERSTANDING NO SIGNALING RESULTING IN NEUROPROTECTION.P50DA000266 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BARABAN, JAY M · 1985 to 2017
$45.2M
Understanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M. · 1998 to 2019
$38.8M
PROJECT III - GENETIC APPROACH TO EXCITATORY TRANSMISSIONP01HD029587 · NICHD · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI LIPTON, STUART A · 1992 to 2016
$21.9M
PW1--A mediator of cell survival by NFKB and cell death by p53P01CA080058 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI AARONSON, STUART A · 2000 to 2016
$20.2M
ALTERNATIVE VACUOLAR TARGETING MECHANISMS IN YEASTR01GM053396 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KLIONSKY, DANIEL J. · 1995 to 2018
$12.1M
Tumor cell metabolism in actionR01CA163591 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI JOSHUA D RABINOWITZ, Eileen P. White · 2012 to 2026
$7.0M
Survival Function of the Fadd-Caspase-8-Flip ComplexR01AI044828 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 1999 to 2016
$6.3M
Chemical Genetic Profiling of Engineered Tumor CellsR01CA097061 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI STOCKWELL, BRENT R. · 2002 to 2016
$4.8M
Molecular and Genetic Control of Programmed Cell DeathR01GM072124 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI ABRAMS, JOHN M · 2004 to 2016
$4.4M
Role of Autophagy in CancerR01CA130893 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI WHITE, EILEEN P. · 2008 to 2017
$3.4M
BCL2 Family Protein Interactions In Cellular Survival StatesR01GM096208 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 2011 to 2018
$2.7M
To the edge of necroptosis and backR01CA169291 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 2012 to 2018
$2.6M
European Research Council 233294Medical Research Council MC_U132670600Medical Research Council MR/M019217/1NCI NIH HHS P01 CA080058NCI NIH HHS R01 CA097061NCI NIH HHS R01 CA130893NCI NIH HHS R01 CA163591NCI NIH HHS R01 CA169291NCI NIH HHS R01 CA170702NIAAA NIH HHS R01 AA021191NIAID NIH HHS R01 AI044828NICHD NIH HHS P01 HD029587NICHD NIH HHS R01 HD066319NIDA NIH HHS P50 DA000266NIDDK NIH HHS R01 DK073336NIDDK NIH HHS R56 DK037034NIGMS NIH HHS R01 GM053396NIGMS NIH HHS R01 GM072124NIGMS NIH HHS R01 GM096208NINDS NIH HHS P50 NS038377NINDS NIH HHS R01 NS086890Wellcome Trust 095317Wellcome Trust 100140
6 · The paper itself

Abstract

Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally referred to as 'accidental cell death' (ACD). In most settings, however, cell death is initiated by a genetically encoded apparatus, correlating with the fact that its course can be altered by pharmacologic or genetic interventions. 'Regulated cell death' (RCD) can occur as part of physiologic programs or can be activated once adaptive responses to perturbations of the extracellular or intracellular microenvironment fail. The biochemical phenomena that accompany RCD may be harnessed to classify it into a few subtypes, which often (but not always) exhibit stereotyped morphologic features. Nonetheless, efficiently inhibiting the processes that are commonly thought to cause RCD, such as the activation of executioner caspases in the course of apoptosis, does not exert true cytoprotective effects in the mammalian system, but simply alters the kinetics of cellular demise as it shifts its morphologic and biochemical correlates. Conversely, bona fide cytoprotection can be achieved by inhibiting the transduction of lethal signals in the early phases of the process, when adaptive responses are still operational. Thus, the mechanisms that truly execute RCD may be less understood, less inhibitable and perhaps more homogeneous than previously thought. Here, the Nomenclature Committee on Cell Death formulates a set of recommendations to help scientists and researchers to discriminate between essential and accessory aspects of cell death.

Indexed as

ApoptosisSignal TransductionAnimalsHumansTerminology as Topic

Identifiers

PMID25236395
PMCPMC4262782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.